315 related articles for article (PubMed ID: 32842811)
1. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.
Zhang N; Shang J; Li C; Zhou K; Du L
Expert Rev Vaccines; 2020 Sep; 19(9):817-829. PubMed ID: 32842811
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
3. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
[TBL] [Abstract][Full Text] [Related]
4. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
Wirblich C; Coleman CM; Kurup D; Abraham TS; Bernbaum JG; Jahrling PB; Hensley LE; Johnson RF; Frieman MB; Schnell MJ
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807241
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
[TBL] [Abstract][Full Text] [Related]
7. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
[TBL] [Abstract][Full Text] [Related]
8. Antibodies and vaccines against Middle East respiratory syndrome coronavirus.
Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L
Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078
[TBL] [Abstract][Full Text] [Related]
9. Prospects for a MERS-CoV spike vaccine.
Zhou Y; Jiang S; Du L
Expert Rev Vaccines; 2018 Aug; 17(8):677-686. PubMed ID: 30058403
[TBL] [Abstract][Full Text] [Related]
10. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
[TBL] [Abstract][Full Text] [Related]
11. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
12. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study.
Tahir Ul Qamar M; Saleem S; Ashfaq UA; Bari A; Anwar F; Alqahtani S
J Transl Med; 2019 Nov; 17(1):362. PubMed ID: 31703698
[TBL] [Abstract][Full Text] [Related]
13. Receptor-binding domain-based subunit vaccines against MERS-CoV.
Zhang N; Tang J; Lu L; Jiang S; Du L
Virus Res; 2015 Apr; 202():151-9. PubMed ID: 25445336
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
[TBL] [Abstract][Full Text] [Related]
15. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
[TBL] [Abstract][Full Text] [Related]
16. Current advancements and potential strategies in the development of MERS-CoV vaccines.
Zhang N; Jiang S; Du L
Expert Rev Vaccines; 2014 Jun; 13(6):761-74. PubMed ID: 24766432
[TBL] [Abstract][Full Text] [Related]
17. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
[TBL] [Abstract][Full Text] [Related]
18. Middle East respiratory syndrome: current status and future prospects for vaccine development.
Du L; Jiang S
Expert Opin Biol Ther; 2015; 15(11):1647-51. PubMed ID: 26414077
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
[TBL] [Abstract][Full Text] [Related]
20. MERS-CoV spike protein: Targets for vaccines and therapeutics.
Wang Q; Wong G; Lu G; Yan J; Gao GF
Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
